Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arbutus Biopharma CorpABUS · Entity 4953 | Director | May 23, 2024 | May 24, 2024 |
| Immunovant, Inc.IMVT · Entity 3632 | Director | April 07, 2026 | April 09, 2026 |
| Myovant Sciences Ltd.MYOV · Entity 115677 | Director | August 23, 2019 | August 27, 2019 |
| Roivant Sciences Ltd.ROIV · Entity 3185 | President and Vant Chair | September 30, 2026 | October 03, 2026 |
| Sio Gene Therapies Inc.SIOX · Entity 130622 | Director | April 15, 2021 | April 19, 2021 |
| Urovant Sciences Ltd.UROV · Entity 140739 | Director | July 09, 2019 | July 11, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arbutus Biopharma Corp
Report date May 23, 2024 · Filed May 24, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.28 · Expires 2034-05-23 | Direct | 67,000 |
Reported balance
After 2024-05-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-05-23 · Grant · Acquired 67,000 · Balance 67,000 F1: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant. F2: The option is fully vested and exercisable as of the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on the date of the grant.
F2: The option is fully vested and exercisable as of the date of the grant.
Immunovant, Inc.
Report date April 07, 2026 · Filed April 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,009,228 |
Reported balance
After 2026-04-07 transaction · row 1
1 source rowRow 1 · 2026-04-07 · Grant · Acquired 174,189 · Balance 1,009,228 F1: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. These units will vest in substantially equal quarterly installments over two years measured from April 1, 2026, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.61 · Expires 2036-04-07 | Direct | 88,325 |
Reported balance
After 2026-04-07 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-07 · Grant · Acquired 88,325 · Balance 88,325 F2: These options were granted pursuant to the Plan. The shares underlying the options will vest in substantially equal quarterly installments over two years measured from April 1, 2026, subject to the Reporting Person's continuous service to the Issuer as of such date. |
Filing footnotes · ownership attribution and instrument terms
F1: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. These units will vest in substantially equal quarterly installments over two years measured from April 1, 2026, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A.
F2: These options were granted pursuant to the Plan. The shares underlying the options will vest in substantially equal quarterly installments over two years measured from April 1, 2026, subject to the Reporting Person's continuous service to the Issuer as of such date.
Myovant Sciences Ltd.
Report date August 23, 2019 · Filed August 27, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.65 · Expires 2029-08-22 | Direct | 58,608 |
Reported balance
After 2019-08-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-08-23 · Grant · Acquired 58,608 · Balance 58,608 F1: 100% of the shares underlying the option vest and become exercisable on the earlier of (a) August 23, 2020, and (b) the date that is one day prior to the Issuer's 2020 Annual General Meeting of Shareholders, subject to the Reporting Person providing continuous service to the Issuer on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares underlying the option vest and become exercisable on the earlier of (a) August 23, 2020, and (b) the date that is one day prior to the Issuer's 2020 Annual General Meeting of Shareholders, subject to the Reporting Person providing continuous service to the Issuer on such date.
Roivant Sciences Ltd.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 13,495,893 |
Reported balance
After 2026-09-30 transaction · row 1
1 source rowRow 1 · 2026-09-30 · Tax withholding · Acquired 40,309 · Balance 13,495,893 F1: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs.
Sio Gene Therapies Inc.
Report date April 15, 2021 · Filed April 19, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.47 · Expires 2031-04-14 | Direct | 42,000 |
Reported balance
After 2021-04-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-04-15 · Grant · Acquired 42,000 · Balance 42,000 F1: 100% of this option will vest on April 15, 2022, subject to the Reporting Person providing continuous service to the Issuer on such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested shares of common stock. All shares of common stock underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of this option will vest on April 15, 2022, subject to the Reporting Person providing continuous service to the Issuer on such date. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested shares of common stock. All shares of common stock underlying the option will become fully vested upon a change in control, as that term is defined in the Issuer's Amended and Restated 2015 Equity Incentive Plan.
Urovant Sciences Ltd.
Report date July 09, 2019 · Filed July 11, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.78 · Expires 2029-07-09 | Direct | 25,000 |
Reported balance
After 2019-07-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-07-09 · Grant · Acquired 25,000 · Balance 25,000 F1: The shares underlying the option shall vest and become exercisable on July 9, 2020, subject to the Reporting Person providing continuous service to the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the option shall vest and become exercisable on July 9, 2020, subject to the Reporting Person providing continuous service to the Issuer through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 21, 2018 Filed Nov 27, 2018 01:40 UTC | Urovant Sciences Ltd. UROV · Entity 140739 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $8.01 | $0.00 |
DisclosureSEC source: 0000899243-18-029672 · doc4.xml · derivative · entry 1 Torti Frank · CIK 0001647805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 50,000 shares Expires 2028-11-21 F1 · derivative.exercise_date: The shares underlying the option shall vest and become exercisable in three equal annual installments beginning on November 9, 2019, subject to the Reporting Person providing continuous service to the Issuer through each such vesting date. Read SEC document |
| November 06, 2018 Filed Nov 8, 2018 22:22 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $22.83 | $0.00 |
DisclosureSEC source: 0001209191-18-057786 · doc4.xml · derivative · entry 1 Torti Frank · CIK 0001647805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2028-11-05 F1 · derivative.exercise_date: 1/3rd of the shares underlying the option vest and become exercisable on November 6, 2019, with the balance of the shares vesting in eight equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer through the vesting date. Read SEC document |
| October 15, 2018 Filed Oct 16, 2018 18:02 UTC | Sio Gene Therapies Inc. AXON · Entity 130622 | GrantStock Option ( Right to Buy) · Derivative | 150,000 | $0.00 Strike: $2.37 | $0.00 |
DisclosureSEC source: 0001209191-18-055178 · doc4.xml · derivative · entry 1 Torti Frank · CIK 0001647805 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Shares · 150,000 shares Expires 2028-10-14 F1 · derivative.exercise_date: The common shares underlying this option vest over a period of three years, with one-third of the common shares vesting on each of the first, second and third anniversaries of September 26, 2018, the date of the Reporting Person's appointment to the Issuer's Board of Directors. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying such option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.